IsoRay found using ticker (ISR) have now 2 analysts covering the stock with the consensus suggesting a rating of ‘Strong_Buy’. The range between the high target price and low target price is between 1 and 1 and has a mean target at 1. Now with the previous closing price of 0.36 this would indicate that there is a potential upside of 177.8%. The 50 day moving average now sits at 0.34 while the 200 day moving average is 0.36. The market cap for the company is $55m. You can visit the company’s website by visiting: https://isoray.com
The potential market cap would be $153m based on the market concensus.
Isoray, through its subsidiary, IsoRay Medical, develops, manufactures, and sells isotope-based medical products and devices for the treatment of cancer and other malignant diseases in the United States and internationally. The company offers CS-1 Cesium-131 brachytherapy seeds for the treatment of prostate, brain, lung, head and neck, gynecological, pelvic/abdominal, and colorectal cancers. It sells its products to facilities or physician practices that utilize various surgical facilities. Isoray was founded in 1998 and is based in Richland, Washington.
